Acadia Pharmaceuticals - Psychosis. Rett. Billion-Dollar Survivor. - $ACAD

ACADIA Pharmaceuticals transformed from a penny stock on the brink of collapse into a biotech leader with the first FDA-approved treatments for Parkinson’s psychosis and Rett syndrome. Discover the turbulent journey of near-misses and scientific breakthroughs that built this billion-dollar CNS powerhouse.---Subscribe to our newsletter on LinkedIn https://www.linkedin.com/build-relation/newsletter-follow?entityUrn=7408775804387491842Follow us on X @emportop---Transcript https://empor.top/us/ACAD I. Introduction & Episode RoadmapII. Founding Context & The Neuroscience Gold Rush (1993-2000)III. The Early Pipeline: Promise and Painful Reality (2000-2010)IV. The Parkinson's Disease Psychosis Bet: Finding the Right DiseaseV. The FDA Approval Drama: Inflection Point #1 (2013-2016)VI. Commercial Launch & The Safety Controversy (2016-2018)VII. Expansion Strategy & Pipeline Diversification (2017-2021)VIII. The Trofinetide Pivot & Rett Syndrome Opportunity (2018-2023)IX. Dementia-Related Psychosis: The Second Act (2021-2024)X. The Business Model & What Makes ACADIA DifferentXI. The Competitive Landscape & Future ThreatsXII. Strategic Analysis: Porter's 5 ForcesXIII. Strategic Analysis: Hamilton's 7 PowersXIV. Bear vs. Bull Case & Investment ConsiderationsXV. Lessons for Founders & Investors: The ACADIA PlaybookXVI. Current State & Future Outlook (2024-2030)XVII. Epilogue: What We LearnedXVIII. Further Reading & Resources